1. Home
  2. WGSWW vs EICB Comparison

WGSWW vs EICB Comparison

Compare WGSWW & EICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGSWW
  • EICB
  • Stock Information
  • Founded
  • WGSWW 2017
  • EICB N/A
  • Country
  • WGSWW United States
  • EICB
  • Employees
  • WGSWW 1000
  • EICB N/A
  • Industry
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • EICB
  • Sector
  • WGSWW Technology
  • EICB
  • Exchange
  • WGSWW Nasdaq
  • EICB Nasdaq
  • Market Cap
  • WGSWW N/A
  • EICB N/A
  • IPO Year
  • WGSWW N/A
  • EICB N/A
  • Fundamental
  • Price
  • WGSWW $0.07
  • EICB $25.03
  • Analyst Decision
  • WGSWW
  • EICB
  • Analyst Count
  • WGSWW 0
  • EICB 0
  • Target Price
  • WGSWW N/A
  • EICB N/A
  • AVG Volume (30 Days)
  • WGSWW 36.6K
  • EICB N/A
  • Earning Date
  • WGSWW 02-18-2025
  • EICB N/A
  • Dividend Yield
  • WGSWW N/A
  • EICB N/A
  • EPS Growth
  • WGSWW N/A
  • EICB N/A
  • EPS
  • WGSWW N/A
  • EICB N/A
  • Revenue
  • WGSWW $305,450,000.00
  • EICB N/A
  • Revenue This Year
  • WGSWW N/A
  • EICB N/A
  • Revenue Next Year
  • WGSWW N/A
  • EICB N/A
  • P/E Ratio
  • WGSWW N/A
  • EICB N/A
  • Revenue Growth
  • WGSWW 50.79
  • EICB N/A
  • 52 Week Low
  • WGSWW $0.17
  • EICB N/A
  • 52 Week High
  • WGSWW $0.21
  • EICB N/A
  • Technical
  • Relative Strength Index (RSI)
  • WGSWW N/A
  • EICB 62.78
  • Support Level
  • WGSWW N/A
  • EICB $24.85
  • Resistance Level
  • WGSWW N/A
  • EICB $24.90
  • Average True Range (ATR)
  • WGSWW 0.00
  • EICB 0.07
  • MACD
  • WGSWW 0.00
  • EICB 0.02
  • Stochastic Oscillator
  • WGSWW 0.00
  • EICB 94.14

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

About EICB Eagle Point Income Company Inc. 7.75% Series B Term Preferred Stock Due 2028

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: